Gregory Blaha, MD
Ophthalmology · Peabody, MANPI 1902998776
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Beaver-visitec International, Inc. at 40.3% of the total. Reporting peaked in 2024 at $952 and has fallen 68.3% since, to $302 in 2025.
Across 17 payments — averaging $197.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beaver-visitec International, Inc.$1K
- Alcon$471
- Vertex$420
- Regeneron$367
- Novartis$230
- Astellas Pharma US Inc$148
- plus $364 from 3 others
Across 24 payments — averaging $3001.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$46K
- Genentech, Inc.$22K
- AbbVie$4K
What the payments were for
- Consulting fees$1,77053%
- Travel & lodging$160%
- Food & beverage$1,56447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beaver-visitec International, Inc. | 2 | $1,350 |
| Alcon | 4 | $471 |
| Vertex | 1 | $420 |
| Regeneron | 3 | $367 |
| Novartis | 2 | $230 |
| Astellas Pharma US Inc | 2 | $148 |
| Genentech, Inc. | 1 | $148 |
| Genentech USA, Inc. | 1 | $115 |
| Dentsply Sirona Inc | 1 | $101 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$321
- VABYSMO$263
- EYLEA HD$136
- BUPARLISIB$122
- EYLEA$107
- Implant Dentistry$101
How this compares
$3,351 in reported general payments places this provider in the 75th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 191 | $10,114 |
| Bromfenac Sodium | 33 | $5,657 |
| Ketorolac Tromethamine | 73 | $1,322 |
| Ofloxacin | 92 | $1,144 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 58 | $1,100 |
| Brimonidine Tartrate | 40 | $559 |
| Timolol Maleate | 26 | $395 |
| Dorzolamide Hcl | 13 | $264 |
| Latanoprost | 19 | $243 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Peabody
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.